Disinvestments, Investments & Funding

Covering more than 5,000 square meters, the facility features 16 modular clean-room clusters that can be expanded or adapted to accommodate future therapeutic advancements.

The acquisition will bring Avidity’s late-stage neuroscience programs under Novartis, giving the company access to a unique RNA-targeting delivery platform.

Bio Farma has been a key partner, demonstrating long-term commitment to equitable access to safe, affordable, and high-quality vaccines worldwide.

Currently, the Pharmacy at Spar network operates 125 stores nationwide, with plans to double that number to 250 in the next three years.

The conference highlights African-led innovations, policy solutions, and research aimed at developing resilient health systems that meet the specific needs of African citizens.

The acquisition mainly focuses on ImCheck’s ICT01, a Phase I/II clinical program aimed at treating acute myeloid leukemia in patients who cannot undergo intensive chemotherapy.

Once completed, Alkermes will add Avadel’s FDA-approved drug, Lumryz (sodium oxybate), to its commercial offerings.

This alliance aligns with Eisai’s global human health care (HHC) philosophy, which seeks to reduce health disparities and alleviate health-related anxiety.

Following the acquisition, Lonza committed to investing 500 million Swiss francs (approximately US$561 million) to enhance and expand the Vacaville site.

With this new purchase, Chugai will take over the development and commercialization of sparsentan in the Asian markets covered by Travere and Renalys’ licensing deal.